Zydus gains USFDA approval, Zynext invests in sickle cell therapy

Zydus Lifesciences has received final approval from the USFDA to manufacture Methenamine Hippurate Tablets USP, 1 gram, indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections. These tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad. The drug generated annual sales of USD 32.6 million in the United States, according to IQVIA data from January 2025. This approval marks the company's 419th, with 483 ANDAs filed since FY 2003-04.